Vaxart, Inc. (VXRT) Earnings Call Transcripts
Vaxart, Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Vaxart, Inc. reported a significant revenue increase to $39.2 million, up from $20.9 million in the same quarter last year, primarily driven by a BARDA contract. The company achieved a net income of $5.2 million, or $0.02 per share, reflecting effective cost management. Management maintained guidance for a cash runway extending into Q2 2027, emphasizing ongoing clinical milestones and operational efficiency as key drivers for future growth.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $39.2 million (beat) |
| Net Income | $5.2 million (beat) |
| EPS | $0.02 (beat) |
| Cash Position | $61 million (positive) |
| Cash Runway | Into Q2 2027 (neutral) |
| R&D Expenses | Reduced (positive) |
Guidance from management
Vaxart expects its cash runway to extend into Q2 2027, maintaining this guidance while focusing on advancing clinical programs and operational efficiency.
What management said
Thanks, David. I'm not going to jump to any conclusions or predetermine any outcomes here. We're blinded to the data. Once we're unblinded, we will evaluate it for appropriate context.
That's a fair question. The third-party review is taking a little longer than anticipated because there are some very specific partnership protocols and some contractual data sharing guidelines that covering the timing of our unwinding. These are deliberate administrative steps required when you work with a contractual partner. All of this is taking really a lot more time than we'd hoped. We are working through those...
What analysts pressed on
Analysts expressed concerns regarding the delays in the COVID-19 trial data release, questioning if the timeline slipping indicates potential issues with data quality or collection processes. There were also inquiries about the company's ability to secure funding for the norovirus program.
Main topics on the call
- Revenue Growth — Vaxart's revenue for Q1 2026 reached $39.2 million, a substantial increase from $20.9 million in Q1 2025, driven largely by the BARDA contract. Management stated, "The growth in revenue was primarily driven by BARDA cont...
- Clinical Trial Updates — The Phase IIb COVID-19 trial's sentinel cohort is nearing completion, with management emphasizing that the primary focus is on safety and immunogenicity rather than efficacy. Dr. Cummings noted, "This cohort was not powe...
- Operational Efficiency — Vaxart has streamlined operations and reduced expenses, which contributed to a net income of $5.2 million for the quarter. CFO Jeroen Grasman stated, "We reduced our R&D and G&A expenses compared to the first quarter of ...
- Board Enhancements — The addition of Dr. James Breitmeyer to the Board is aimed at strengthening clinical and regulatory oversight as Vaxart approaches critical data milestones. CEO Steve Lo remarked, "His experience and track record... prov...
Read the full Vaxart, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Vaxart, Inc.
Vaxart, Inc. (VXRT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on OTCPK and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning November 19, 2020 to August 7, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Vaxart, Inc. earnings call transcripts on record, spanning November 19, 2020 to August 7, 2026. Based on this history, Vaxart, Inc. reports quarterly. The most recent call on file is dated August 7, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VXRT
- Exchange
- OTCPK
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 28
- First call
- November 19, 2020
- Most recent
- August 7, 2026
- Reporting cadence
- quarterly